Anavex Life Sciences (AVXL) Prepaid Assets (2011 - 2025)
Anavex Life Sciences recorded quarterly Prepaid Assets of $396000.0 in Q4 2025, down 7.69% quarter-over-quarter from $429000.0 in Q3 2025, and down 44.3% year-over-year from $711000.0 in Q4 2024.
Anavex Life Sciences' Prepaid Assets history runs 14 years deep, the most recent figure standing at $396000.0 for Q4 2025.
- In Q4 2025, Prepaid Assets fell 44.3% year-over-year to $396000.0; the TTM figure through Dec 2025 stood at $396000.0 (down 44.3% YoY), while the FY2025 annual figure was $429000.0, down 53.92% from the prior year.
- Prepaid Assets came in at $396000.0 for Q4 2025 at Anavex Life Sciences, down from $429000.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.3 million in Q1 2024 to a low of $258198.0 in Q2 2021.
- A 5-year average of $628516.9 and a median of $558802.5 in 2022 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets soared 111.31% in 2023 and tumbled 57.7% in 2025, its largest moves.
- Anavex Life Sciences' Prepaid Assets stood at $377860.0 in 2021, then jumped by 73.51% to $655643.0 in 2022, then grew by 15.31% to $756000.0 in 2023, then decreased by 5.95% to $711000.0 in 2024, then tumbled by 44.3% to $396000.0 in 2025.
- According to Business Quant data, Prepaid Assets over the past three periods registered $396000.0, $429000.0, and $448000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 396,000.00 |
| Sep 30, 2025 | 429,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Mar 31, 2025 | 702,000.00 |
| Dec 31, 2024 | 711,000.00 |
| Sep 30, 2024 | 931,000.00 |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 756,000.00 |
| Sep 30, 2023 | 653,000.00 |
| Jun 30, 2023 | 827,572.00 |
| Mar 31, 2023 | 981,774.00 |
| Dec 31, 2022 | 655,643.00 |
| Sep 30, 2022 | 354,000.00 |
| Jun 30, 2022 | 461,963.00 |
| Mar 31, 2022 | 464,605.00 |
| Dec 31, 2021 | 377,860.00 |
| Sep 30, 2021 | 371,914.00 |
| Jun 30, 2021 | 258,198.00 |
| Mar 31, 2021 | 386,809.00 |
| Dec 31, 2020 | 398,840.00 |
| Sep 30, 2020 | 443,839.00 |
| Jun 30, 2020 | 438,631.00 |
| Mar 31, 2020 | 305,559.00 |
| Dec 31, 2019 | 234,972.00 |
| Sep 30, 2019 | 500,998.00 |
| Jun 30, 2019 | 459,618.00 |
| Mar 31, 2019 | 849,642.00 |
| Dec 31, 2018 | 1.16 Mn |
| Sep 30, 2018 | 1.25 Mn |
| Jun 30, 2018 | 858,560.00 |
| Mar 31, 2018 | 150,660.00 |
| Dec 31, 2017 | 235,390.00 |
| Sep 30, 2017 | 335,928.00 |
| Jun 30, 2017 | 52,694.00 |
| Sep 30, 2016 | 180,124.00 |
| Jun 30, 2015 | 16,054.00 |
| Mar 31, 2015 | 51,985.00 |
| Dec 31, 2014 | 67,576.00 |
| Sep 30, 2014 | 89,117.00 |
| Jun 30, 2014 | 18,919.00 |
| Mar 31, 2014 | 28,478.00 |
| Dec 31, 2013 | 52,825.00 |
| Sep 30, 2013 | 48,375.00 |
| Sep 30, 2011 | 9,630.00 |